Piramal Pharma Ltd
₹138.35
(1.94%)
Mon, 23 Mar 2026, 05:32 pm
Health Technology
Pharmaceuticals: Major
24.5KPiramal Pharma Debt to Equity Ratio
| Particulars | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 928.67 | 327.83 |
| Price to book ratio | 0 | 1.21 | 2.16 | 3.65 |
| Price to sales ratio | 0 | 1.15 | 2.02 | 3.27 |
| Price to cash flow ratio | 0 | 28.25 | 29.29 | 59.72 |
| Enterprise value | 0 | 130.46B | 206.27B | 341.96B |
| Enterprise value to EBITDA ratio | 0 | 20.36 | 16.37 | 22.54 |
| Debt to equity ratio | 0.62 | 0.83 | 0.60 | 0.60 |
| Return on equity % | 0 | -2.77 | 0.24 | 1.14 |
Piramal Pharma Ltd Debt to Equity Ratio
The Piramal Pharma Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Piramal Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Piramal Pharma Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Piramal Pharma Ltd (NSE: PPLPHARMA, BSE: 543635) is currently trading at ₹138.35, with a market capitalization of ₹183.77B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Piramal Pharma Ltd Debt to Equity Ratio is essential for fundamental analysis.
Piramal Pharma Ltd Debt to Equity Ratio Current Value
The current Piramal Pharma Ltd Debt to Equity Ratio stands at 0.60.
The Piramal Pharma Ltd Debt to Equity Ratio remains stable, indicating consistent financial performance.
Piramal Pharma Ltd Debt to Equity Ratio Historical Trend
The Piramal Pharma Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.60
- 2023: 0.60
- 2022: 0.83
- 2021: 0.62
The decline in Piramal Pharma Ltd Debt to Equity Ratio indicates improving financial efficiency or better earnings growth.
What Piramal Pharma Ltd Debt to Equity Ratio Indicates for Investors
The Piramal Pharma Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Piramal Pharma Ltd Debt to Equity Ratio Analysis Summary
The Piramal Pharma Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Piramal Pharma Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Piramal Pharma Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800